The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.

Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type I interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeutic compositions and methods for enhancing or improving an individual's response to yeast-based immunotherapy, based on the individual's sensitivity to type 1 interferons (T1IFNs).

The invention relates to materials, methods and devices useful for sampling biological molecules, including biomarkers and/or metabolites. In particular, the invention relates to surface functionalised xerogels and surface functionalised poly(dimethyl) siloxane (PDMS), devices comprising those materials, and methods of using the materials and devices for sampling, analysing or detecting biological molecules.

Among the various aspects of the present disclosure is the provision of compositions and methods for treating autoimmune diseases (e.g., multiple sclerosis).

Subject of the invention is a composition comprising at least one fragment of the peptide ESAT-6 and at least one fragment of the peptide CFP-10. Preferably, the fragments comprise at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater. The invention also relates to diagnostic methods using the composition.

The present disclosure provides a method for screening and preparing an immunomodulator. The present disclosure further relates to a use of an immunosuppressant in the treatment of immune-related diseases.